Medical Oncology Associates, PS DBA Summit Cancer Centers

Spokane, Washington 99208

0 studies enrolling now · 9 studies all time

What they study most

Advanced Estrogen Receptor Positive HER2- Breast Cancer, Androgen-Resistant Prostatic Neoplasms, BRAF V600E-mutant Metastatic Colorectal Cancer, CLL, Castration Resistant Prostatic Neoplasms, Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Renal Cell Carcinoma, Small-cell Lung Cancer, Solid Tumor, Unspecified, Adult

Studies at this site

• A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) — Recruiting now
• A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies — Running, not enrolling
• Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer — Completed
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• Derazantinib and Atezolizumab in Patients With Urothelial Cancer — Completed
• Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL — Withdrawn before enrolling
• Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer — Completed
• GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer — Stopped early